Main contents starts here
Press Releases 2004
- December 20, 2004
Takeda Announces to Place its Anti-Diabetic Agent TAK-559 on Clinical Hold - December 16, 2004
TAP Submits New Drug Application for Febuxostat for The Management of Hyperuricemia in Chronic Gout - November 29, 2004
European Mutual Recognition Procedure approves Blopress® for the treatment of chronic heart failur - November 4, 2004
Mitsubishi Pharma and Takeda to Terminate License Agreement on an Agent for Cardiac Diseases - November 1, 2004
Sucampo and Takeda to Enter into an Agreement for a New Drug, Lubiprostone,for Chronic Constipation and Constipation-predominant Irritable Bowel Syndrome - October 29, 2004
Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication, Actoplus Met™ (pioglitazone HCl and metformin HCl) - October 7, 2004
Takeda Announces Alliance with BioNumerik to Market Tavocept™, Phase III Chemoprotective Agent, in U.S. and Canada - September 24, 2004
Takeda Submits New Drug Application for Ramelteon, an Investigational Sleep Drug - August 31, 2004
New CHARM* analysis adds further weight to effectiveness of Candesartan in treating heart failure - August 16, 2004
Higher Dosage Form of Candesarten Cilexetil Approved in Europe - July 28, 2004
Takeda and Lexicon Genetics to Establish Collaboration to Develop New Drugs for High Blood Pressure - July 7, 2004
The Revision of Remuneration Rule for Employees' Inventions - June 28, 2004
Landmark PROactive Trial Investigates Effect of ACTOS (pioglitazone HCl) on Cardiovascular Disease Progression
More than 5,000 patients with type 2 diabetes studied - May 6, 2004
Takeda Research Investment, Inc. to Invest in Three Biotechnology Ventures - April 27, 2004
Takeda Announced a Year-end Dividend of the Fiscal Year Ended March 31, 2004 - April 8, 2004
Takeda Submits Application for the Use of Candesartan in the Treatment of Chronic Heart Failure - March 10, 2004
New data on the effect of candesartan cilexetil on NYHA functional class in a broad spectrum of heart failure patients - February 27, 2004
DIRECTing the fight against vision impairment in diabetes
Randomisation phase of landmark Programme of candesartan cilexetil in diabetic retinopathy completed - February 13, 2004
Takeda Global Concert Series Japan Tour by London Symphony Orchestra - February 6, 2004
"Takeda Wing" to Open at the Oxford Centre for Diabetes - January 30, 2004
Takeda Exercises Rights to License Agreement on Alizyme's Obesity Drug in Japan - January 27, 2004
Summary of Consolidated Financial Results for the Fiscal 2003 Third Quater (from October 1 to December 31,2003) - January 8, 2004
Andrx And Takeda Collaborate On Combination Product Of Actos And Fortamet